INCY INCYTE CORP
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 879169 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY24.9%
TTM net income YoY-66.1%
TTM EPS YoY-66.8%
Revenue 3-yr CAGR18.5%
Net income 3-yr CAGR-1.7%
Margins
Gross margin92.7%
Operating margin10.4%
Net margin6.7%
FCF margin—
EBITDA margin12.1%
Returns
ROE7.8%
ROA5.9%
ROIC (approx.)13.9%
Asset turnover0.88x
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.84x
Interest coverage267.97x
Cash quality & payout
Operating cash flow / net income1.85x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.56B | $1.67B | $1.27B | $1.51B | $1.37B | $1.22B | $1.05B | $1.18B |
| Cost of revenue | $108.74M | $104.96M | $104.52M | $121.17M | $99.00M | $78.77M | $73.19M | $88.48M |
| Gross profit | $1.45B | $1.57B | $1.17B | $1.39B | $1.27B | $1.14B | $979.71M | $1.09B |
| R&D expense | $1.79B | $516.95M | $515.90M | $611.37M | $506.58M | $494.92M | $437.28M | $466.03M |
| SG&A expense | $364.27M | $351.74M | $328.09M | $390.41M | $329.08M | $331.02M | $325.69M | $326.71M |
| Operating income | -$708.36M | $697.90M | $301.12M | $335.86M | $443.52M | $530.31M | $205.17M | $301.51M |
| Interest expense | $605,000 | $582,000 | $569,000 | $582,000 | $592,000 | $594,000 | $660,000 | $419,000 |
| Pretax income | -$688.85M | $751.51M | $343.60M | $389.94M | $482.31M | $558.01M | $234.19M | $313.72M |
| Income tax | $95.95M | $165.91M | $40.27M | $90.66M | $58.14M | $153.01M | $75.99M | $112.51M |
| Net income | -$784.80M | $585.61M | $303.33M | $299.28M | $424.17M | $405.00M | $158.20M | $201.21M |
| EBITDA | -$684.19M | $724.37M | $324.92M | $359.84M | $467.54M | $553.23M | $227.53M | $324.25M |
| EPS (basic) | -3.86 | 2.92 | 1.52 | — | 2.17 | 2.09 | 0.82 | — |
| EPS (diluted) | -3.86 | 2.81 | 1.47 | — | 2.11 | 2.04 | 0.80 | — |
| Weighted avg. shares (diluted) | 203.25M | 208.22M | 206.83M | — | 201.43M | 198.74M | 198.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.28B | $3.98B | $3.46B | $3.10B | $2.46B | $1.96B | $1.94B | $1.69B |
| Inventory | $134.25M | $112.54M | $115.62M | $101.06M | $83.45M | $83.42M | $63.98M | $58.87M |
| Current assets | $5.52B | $6.03B | $5.48B | $5.02B | $4.28B | $3.64B | $3.51B | $3.24B |
| PP&E, net | $701.10M | $709.47M | $720.17M | $730.88M | $798.63M | $798.54M | $765.36M | $763.41M |
| Goodwill | $133.00M | $133.00M | $133.00M | $133.00M | $155.59M | $155.59M | $155.59M | $155.59M |
| Total assets | $7.29B | $7.87B | $7.34B | $6.96B | $6.33B | $5.82B | $5.75B | $5.44B |
| Current liabilities | $1.44B | $1.31B | $1.49B | $1.52B | $1.34B | $1.28B | $1.72B | $1.64B |
| Total liabilities | $1.64B | $1.53B | $1.72B | $1.79B | $1.68B | $1.65B | $2.08B | $2.00B |
| Shareholders' equity | $5.64B | $6.34B | $5.62B | $5.17B | $4.65B | $4.17B | $3.67B | $3.45B |
| Shares outstanding | 204.00M | 200.98M | 199.95M | 198.46M | 196.13M | 194.12M | 193.78M | 193.43M |
| Cash flow statement | ||||||||
| Operating cash flow | -$675.32M | $507.66M | $369.35M | $543.30M | $559.39M | $44.74M | $266.07M | $381.22M |
| Investing cash flow | -$44.34M | -$51.79M | -$88.20M | -$37.42M | -$47.42M | -$18.87M | $1.10M | -$21.46M |
| Financing cash flow | $13.94M | $65.46M | $84.82M | $137.74M | -$12.78M | -$11.25M | -$12.68M | $20.39M |
| Depreciation & amortization | $24.18M | $26.48M | $23.80M | $23.98M | $24.02M | $22.92M | $22.36M | $22.73M |
| Stock-based compensation | $69.80M | $67.30M | $64.13M | $62.16M | $61.60M | $64.60M | $60.98M | $71.72M |
| Share buybacks | — | — | — | $0 | $0 | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.